A Phase 2 Safety, Tolerability, and Proof-of-Concept Study of VGL101 in Patients With Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia (ALSP) (The Ignite Study)
Latest Information Update: 06 Dec 2024
Price :
$35 *
At a glance
- Drugs Iluzanebart (Primary)
- Indications Leukoencephalopathies
- Focus Adverse reactions
- Sponsors Vigil Neuroscience
- 03 Dec 2024 Planned primary completion date changed from 31 Jul 2024 to 7 Mar 2025.
- 22 Apr 2024 Planned number of patients changed from 15 to 20.
- 22 Apr 2024 Planned End Date changed from 30 Jun 2024 to 31 Mar 2027.